Avalo Therapeutics (AVTX)
(Delayed Data from NSDQ)
$7.00 USD
-2.05 (-22.65%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $7.54 +0.54 (7.71%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.00 USD
-2.05 (-22.65%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $7.54 +0.54 (7.71%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Zacks News
Are Options Traders Betting on a Big Move in Avalo Therapeutics (AVTX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Avalo Therapeutics (AVTX) stock based on the movements in the options market lately.
Wall Street Analysts Predict a 191% Upside in Avalo Therapeutics, Inc. (AVTX): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 191.3% in Avalo Therapeutics, Inc. (AVTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Predict a 230% Upside in Avalo Therapeutics, Inc. (AVTX): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 230.1% upside potential for Avalo Therapeutics, Inc. (AVTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is Artelo Biosciences, Inc. (ARTL) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Artelo Biosciences, Inc. (ARTL) and Avalo Therapeutics, Inc. (AVTX) have performed compared to their sector so far this year.
Do Options Traders Know Something About Avalo (AVTX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Avalo (AVTX) stock based on the movements in the options market lately.